News & Updates
Showing Oncology articles
Showing
Add-on bevacizumab ups hypertension risk in CRC patients
The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?
Hypofractionated radiotherapy (HFRT) is not superior to conventionally fractionated radiotherapy (CFRT) in providing survival benefits to patients with stage I nonsmall cell lung cancer (NSCLC), but HFRT is preferable due to its convenience and lower costs, according to a study.
Tislelizumab–chemotherapy combo poised as new first-line option for advanced gastric cancer
Adding the anti-PD-1 monoclonal antibody tislelizumab to chemotherapy in the first-line treatment of PD-1-positive advanced gastric or gastroesophageal junction adenocarcinoma appears to produce significant and clinically meaningful improvements in survival outcomes while having an acceptable safety profile, according to interim data from the phase III RATIONALE 305 trial.
Palliative RT relieves pain in end-stage liver cancer
Treatment with single fraction radiation therapy (RT) results in lesser hepatic pain in most patients with end-stage hepatocellular carcinoma (HCC) or liver metastases, according to a study presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Preop chemotherapy confers survival advantage in colorectal cancer with liver metastasis
Giving chemotherapy to patients with synchronous and unresectable liver metastases from colorectal cancer before undergoing primary tumour resection helps boost survival outcomes, according to a phase III trial presented at this year’s ASCO Gastrointestinal Cancer Symposium (ASCO GI).
Tumour response-speed heterogeneity linked to poor survival in metastatic colorectal cancer
Tumour response-speed heterogeneity to first-line chemotherapy is predictive of early disease progression and shorter survival in patients with metastatic colorectal cancer, reveals a study.
Circulating 11-oxygenated androgens predict survival in localized prostate cancer
In men with localized prostate cancer undergoing radical prostatectomy and treated with 5α-reductase inhibitor (5-ARI), preoperative levels of circulating 11-oxygenated androgens can indicate either disease progression or improved survival, a recent study has found.
